SequelSEC

Aldeyra Therapeutics, Inc. ALDX

Pharmaceutical Preparations · CIK 0001341235 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$35.27M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Aldeyra Therapeutics, Inc. (ALDX) reported net income of -$33.85M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Aldeyra Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aldeyra Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$35.27M-$60.12M-$42.79M-$62.68M-$56.22M-$36.42M-$63.07M-$39.70M-$22.49MUnavailable
Net income-$33.85M-$55.85M-$37.54M-$62.02M-$57.78M-$37.55M-$60.83M-$38.89M-$22.34MUnavailable
Research & development$25.66M$48.22M$29.46M$47.31M$44.94M$24.68M$44.35M$29.82M$16.30MUnavailable
Weighted-average diluted sharesshares 60.06Mshares 59.48Mshares 58.94Mshares 58.41Mshares 54.04MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailable-$57.78M-$38.03M-$62.14M-$38.89MUnavailableUnavailable
Income tax expense$0$1.00K$0$0$0-$479.26K-$1.31M$0$0Unavailable
Diluted EPS$-0.56$-0.94$-0.64$-1.06$-1.07UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$9.60M$11.89M$13.34M$15.37M$11.28M$9.99M$12.15M$9.88M$6.19MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Aldeyra Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$70.04M$54.53MUnavailable$144.42M$229.79M$77.86M$44.43M$47.36M$20.02MUnavailable
Total assets$72.06M$104.61M$148.33M$181.29M$233.14M$83.35M$75.52M$95.09M$44.17MUnavailable
Current assets$71.78M$104.07M$147.81M$181.02M$232.75M$83.06M$75.17M$94.77M$43.97MUnavailable
Total liabilities$27.81M$33.60M$28.53M$30.28M$27.40M$23.84M$27.44M$8.47M$4.57MUnavailable
Current liabilities$27.81M$18.60M$22.26M$15.36M$11.77M$12.41M$12.91M$8.47M$3.35MUnavailable
Total equity incl. NCI$44.25M$71.00M$119.80M$151.01M$205.74M$59.51M$48.08M$86.62M$39.60MUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$0$15.00M$0$14.92M$15.50M$11.43M$14.53M$16.04M$1.22MUnavailable
Accounts payable$158.46K$180.45K$1.34M$133.62K$1.02M$381.64K$808.30K$3.05M$1.00MUnavailable

Cash flow

Aldeyra Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$33.35M-$43.21M-$30.33M-$56.64M-$42.56M-$37.49M-$44.98M-$29.86M-$19.22MUnavailable
Capital expendituresUnavailableUnavailable$0$16.32K$7.81KUnavailable$9.53K$262.97K$24.76KUnavailable
Investing cash flow$47.74M-$44.92M$30.00M-$29.95M-$7.81K$29.02M$18.48M-$23.34M-$10.20MUnavailable
Financing cash flow$1.12M-$171.42K-$1.27M$1.22M$194.50M$41.90M$23.58M$80.53M$37.43MUnavailable
Net change in cash$15.51M-$88.30M-$1.60M-$85.37M$151.93M$33.43M-$2.93M$27.33M$8.01MUnavailable
Stock-based compensation$6.09M$7.97M$5.75M$8.29M$7.11M$7.08M$8.08M$4.14M$2.71MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Aldeyra Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailable-$56.65M-$42.56MUnavailable-$44.99M-$30.12M-$19.25MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.58x5.59x6.64x11.78x19.77x6.69x5.82x11.18x13.11xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALDX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2016-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2016-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.